Trial Profile
A Randomized Double-Blinded Placebo-Controlled Exploratory Study of Intravenous Immunoglobulin (NewGam 10%) in Amnestic Mild Cognitive Impairment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2022
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Amnesia; Mild cognitive impairment
- Focus Therapeutic Use
- 25 Oct 2022 Status changed from active, no longer recruiting to completed.
- 25 Sep 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 06 Sep 2018 Planned End Date changed from 1 Jul 2018 to 1 Dec 2018.